Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the Board of Directors (the “Board”) nominates healthcare executive Laura J. Hamill to be elected as a Class II director at the Company’s 2020 annual meeting of stockholders (the “Annual Meeting”).

https://www.globenewswire.com/news-release/2020/04/24/2021711/0/en/Y-mAbs-Announces-Appointment-of-Laura-J-Hamill-to-its-Board-of-Directors.html